BioSpace News Archive

Pharm Country

Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted to the U.S. Food and Drug Administration (FDA) its Biologics License Application (BLA) for approval of remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).

January 31, 2023
·
12 min read
Business

Amgen Posts Full Transcript and Audio Replay of Fourth Quarter and Full Year 2022 Earnings Webcast

Amgen posted the full transcript and audio replay of the company’s 2022 fourth quarter and full year financial results webcast from earlier.

January 31, 2023
·
1 min read